US FDA Approves Youcare Pharmaceutical Subsidiary's Clinical Trial for Hepatitis B Injection

MT Newswires Live09-23

The US Food and Drug Administration approved Youcare Pharmaceutical (SHA:688658) subsidiary Beijing Yuekang Kechuang Pharmaceutical Technology's clinical trial for its YKYY013 injection, according to a Tuesday filing with the Shanghai bourse.

The injection is indicated for chronic hepatitis B virus, the filing said.

Shares closed 3% lower on Tuesday.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment